A cost-utility analysis of pregabalin versus duloxetine for the treatment of painful diabetic neuropathy (Q43601105)

25 November 2017

A cost-utility analysis of pregabalin versus duloxetine for the treatment of painful diabetic neuropathy (English)

1 reference

25 November 2017

Brandon K Bellows

1

1 reference

25 November 2017

Arati Dahal

series ordinal

2

1 reference

25 November 2017

Tianze Jiao

series ordinal

3

1 reference

25 November 2017

Joseph Biskupiak

series ordinal

4

1 reference

25 November 2017

18 April 2012

1 reference

Journal of Pain and Palliative Care Pharmacotherapy

25 November 2017

1 reference

25 November 2017

26

1 reference

25 November 2017

2

1 reference

25 November 2017

153-164

1 reference

Diabetic neuropathies: a statement by the American Diabetes Association

25 November 2017

1 reference

https://api.crossref.org/works/10.3109%2F15360288.2012.671240

Neuropathic pain: aetiology, symptoms, mechanisms, and management

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15360288.2012.671240

Epidemiology and impact on quality of life of postherpetic neuralgia and painful diabetic neuropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15360288.2012.671240

Natural history of peripheral neuropathy in patients with non-insulin-dependent diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15360288.2012.671240

A multicentre study of the prevalence of diabetic peripheral neuropathy in the United Kingdom hospital clinic population

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15360288.2012.671240

Painful diabetic polyneuropathy: epidemiology, pain description, and quality of life

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15360288.2012.671240

Diabetic peripheral neuropathy and quality of life.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15360288.2012.671240

The health care costs of diabetic peripheral neuropathy in the US.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15360288.2012.671240

Evidence-based guideline: Treatment of painful diabetic neuropathy: report of the American Academy of Neurology, the American Association of Neuromuscular and Electrodiagnostic Medicine, and the American Academy of Physical Medicine and Rehabilitati

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15360288.2012.671240

A cost-utility comparison of four first-line medications in painful diabetic neuropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15360288.2012.671240

Economic evaluation of oral treatments for neuropathic pain

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15360288.2012.671240

A cost-effectiveness comparison of desipramine, gabapentin, and pregabalin for treating postherpetic neuralgia

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15360288.2012.671240

Efficacy and safety of pregabalin 600 mg/d for treating painful diabetic peripheral neuropathy: a double-blind placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15360288.2012.671240

Efficacy of pregabalin in neuropathic pain evaluated in a 12-week, randomised, double-blind, multicentre, placebo-controlled trial of flexible- and fixed-dose regimens

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15360288.2012.671240

Pregabalin relieves symptoms of painful diabetic neuropathy: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15360288.2012.671240

Relief of painful diabetic peripheral neuropathy with pregabalin: a randomized, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15360288.2012.671240

Pregabalin for the treatment of painful diabetic peripheral neuropathy: a double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15360288.2012.671240

Pregabalin in the treatment of refractory neuropathic pain: results of a 15-month open-label trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15360288.2012.671240

Duloxetine, pregabalin, and duloxetine plus gabapentin for diabetic peripheral neuropathic pain management in patients with inadequate pain response to gabapentin: an open-label, randomized, noninferiority comparison.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15360288.2012.671240

Pregabalin for relief of neuropathic pain associated with diabetic neuropathy: a randomized, double-blind study

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15360288.2012.671240

Duloxetine vs. placebo in patients with painful diabetic neuropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15360288.2012.671240

A double-blind, randomized multicenter trial comparing duloxetine with placebo in the management of diabetic peripheral neuropathic pain

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15360288.2012.671240

Duloxetine versus routine care in the long-term management of diabetic peripheral neuropathic pain

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15360288.2012.671240

Duloxetine for patients with diabetic peripheral neuropathic pain: a 6-month open-label safety study

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15360288.2012.671240

A randomized controlled trial of duloxetine in diabetic peripheral neuropathic pain.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15360288.2012.671240

An open-label 52-week clinical extension comparing duloxetine with routine care in patients with diabetic peripheral neuropathic pain.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15360288.2012.671240

Medication adherence and healthcare costs among patients with diabetic peripheral neuropathic pain initiating duloxetine versus pregabalin.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15360288.2012.671240

Changes in opioid use and healthcare costs among U.S. patients with diabetic peripheral neuropathic pain treated with duloxetine compared with other therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15360288.2012.671240

Opioid use and healthcare costs among patients with DPNP initiating duloxetine versus other treatments

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15360288.2012.671240

Opioid utilization and health-care costs among patients with diabetic peripheral neuropathic pain treated with duloxetine vs. other therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15360288.2012.671240

Clinical characteristics, pharmacotherapy, and healthcare resource use among patients with diabetic neuropathy newly prescribed pregabalin or gabapentin.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15360288.2012.671240

Healthcare utilization in people with postherpetic neuralgia and painful diabetic peripheral neuropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15360288.2012.671240

Pain severity in diabetic peripheral neuropathy is associated with patient functioning, symptom levels of anxiety and depression, and sleep.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15360288.2012.671240

EuroQol: the current state of play

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15360288.2012.671240

Clinical effectiveness, tolerability and cost-effectiveness of newer drugs for epilepsy in adults: a systematic review and economic evaluation

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15360288.2012.671240

Cost-utility of enoxaparin compared with unfractionated heparin in unstable coronary artery disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15360288.2012.671240

Handling uncertainty in cost-effectiveness models

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15360288.2012.671240

Cost-effectiveness of different screening strategies for osteoporosis in postmenopausal women

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15360288.2012.671240

Cost-effectiveness of six strategies for Helicobacter pylori diagnosis and management in uninvestigated dyspepsia assuming a high resource intensity practice pattern

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15360288.2012.671240

The cost-effectiveness of cyclooxygenase-2 selective inhibitors in the management of chronic arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15360288.2012.671240

Cost effectiveness of duloxetine in the treatment of diabetic peripheral neuropathic pain in the UK.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15360288.2012.671240

Cost-effectiveness of duloxetine versus routine treatment for U.S. patients with diabetic peripheral neuropathic pain

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15360288.2012.671240

Burden of illness in painful diabetic peripheral neuropathy: the patients' perspectives.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15360288.2012.671240

10.3109/15360288.2012.671240

21 January 2018

Identifiers

DOI

1 reference

25 November 2017

1 reference